Evidence map›Paper›PMID 32640027›Full record

ArticleThe international journal of neuropsychopharmacology2020

Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer's Disease.

X Anton Alvarez, Irene Alvarez, Antia Martinez, Iria Romero, Concha Benito, Irene Suarez, Silvia Mourente, Manuel Fantini, Jesús Figueroa, Manuel Aleixandre and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of neuropsychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Review
  3. Cerebral amyloid angiopathy: a narrative review.Frontiers in aging neuroscience · 2025
    Review
  4. Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

X Anton AlvarezMedinova Institute of Neurosciences, Clinica RehaSalud, A Coruña, Spain.
Irene AlvarezMedinova Institute of Neurosciences, Clinica RehaSalud, A Coruña, Spain.
Antia MartinezComplexo Hospitalario Universitario de Ourense, Ourense, Spain.
Iria RomeroMedinova Institute of Neurosciences, Clinica RehaSalud, A Coruña, Spain.
Concha BenitoMedinova Institute of Neurosciences, Clinica RehaSalud, A Coruña, Spain.
Irene SuarezMedinova Institute of Neurosciences, Clinica RehaSalud, A Coruña, Spain.
Silvia MourenteHospital Quirónsalud, A Coruña, Spain.
Manuel FantiniHospital HM Modelo, A Coruña, Spain.
Jesús FigueroaMedinova Institute of Neurosciences, Clinica RehaSalud, A Coruña, Spain.
Manuel AleixandreSchool of Psychology, Granada University, Granada, Spain.
Carlos LinaresComplejo Asistencial HHSCJ, Málaga, Spain.
Dafin MuresanuDepartment of Clinical Neurosciences, University of Medicine and Pharmacy "Iuliu Hațieganu," Cluj-Napoca, Romania.
Stefan WinterEver NeuroPharma, Unterach, Austria.
Herbert MoesslerComamo OG, Mondsee, Austria.
Complejo Hospitalario de Ourense · ESComplexo Hospitalario Universitario A Coruña · ESEVER Neuro Pharma (Austria) · ATHospital Quirónsalud Barcelona · ESIuliu Hațieganu University of Medicine and Pharmacy · ROUniversidad de Granada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serum vascular endothelial growth factor (VEGF) increases with Alzheimer's disease (AD) severity and may prevent cognitive decline. However, information on the influence of AD drug therapy on circulating VEGF is limited. This study assessed changes in serum VEGF levels and its association with clinical and functional responses in mild to moderate AD patients who were treated with Cerebrolysin, donepezil, or the combined therapy in a randomized, controlled trial. Treatment with Cerebrolysin plus donepezil reduced elevated serum VEGF levels and improved functioning and cognition significantly compared with donepezil alone in patients with advanced AD, and treatment differences were more pronounced in patients with higher VEGF levels. Our results indicate that the combined therapy reversed the increase of serum VEGF in advanced AD, which was associated with cognitive and functional responses, particularly in patients with high baseline VEGF.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmino AcidsDonepezilDrug Therapy, CombinationFemaleHumansMaleNootropic AgentsOutcome Assessment, Health CareVascular Endothelial Growth Factor AAmino AcidscerebrolysinDonepezilNootropic AgentsVascular Endothelial Growth Factor AVEGFA protein, humanAlzheimer’s disease (AD)Cerebrolysincombined therapydonepezilvascular endothelial growth factor (VEGF)

Identifiers

PMID32640027
PMCPMC7710915
OpenAlexW3040788043

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.